KTD-092

• Description :

  KTD-092 is a hit for DYRK1A inhibition, with an IC50 of 22 nM for human DYRK1A. KTD-092 can be used in the research for Down syndrome (DS), Alzheimer's disease (AD), autism spectrum disorder (ASD), diabetes and other neurodegenerative diseases[1].

• UNSPSC :

  12352005

• Target :

  DYRK

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease; Neurological Disease

• Smiles :

  CCN1C=NN=C1C2=NC(NC(C3=CC(OC)=C(C=C3OC)OC)=O)=CC=C2

• Molecular Formula :

  C19H21N5O4

• Molecular Weight :

  383.40

• References & Citations :

  [1]Sujeong Hong, et al. Discovery of 2- (1,2,4-triazol-3-yl) pyridine KTD-092 as a novel DYRK1A. Wiley Online Library inhibitor. 2025.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  DYRK1